Tag: KRAS inhibitor
Breakthrough Drug Targeting ‘Undruggable’ KRAS Mutation Nearly Doubles Pancreatic Cancer Survival
New targeted therapy daraxonrasib successfully inhibits KRAS mutations in pancreatic cancer, nearly doubling survival times. Clinical trial shows 60% reduction…
Revolution Medicines Ships Experimental Pancreatic Cancer Drug Under Early Access
Revolution Medicines begins expanded access program for daraxonrasib targeting KRAS G12C mutations. FDA submission planned as five-year pancreatic cancer survival…
New Drug Daraxonrasib Nearly Doubles Pancreatic Cancer Survival in Phase 3 Trial
Daraxonrasib nearly doubles survival in advanced pancreatic cancer patients with KRAS G12C mutations. The breakthrough targets a previously "undruggable" protein…
Submit Your Paper to GMJ
No APC until January 2027.